Skip to content 
Resectable pancreatic cancer is the kind that can be surgically removed with a reasonable shot at cure. Unresectable means the tumour has grown into or wrapped around structures that no surgeon can safely take out. The line between the two is drawn on imaging, almost always a contrast-enhanced CT, and that line decides what the next year of treatment looks like. Only about one in five patients are resectable when they’re first diagnosed, which is partly why this disease still has such a bad reputation. A Gastroenterologist in Mumbai seeing these cases spends most of the first visit working out which category the patient falls into.
According to Dr. Vipulroy Rathod, Gastroenterologist in Mumbai, “Patients are sometimes told their pancreatic cancer is operable when the imaging actually shows borderline involvement of a major vessel, and they end up in surgery that gets abandoned mid-procedure, which is the worst possible outcome and almost always preventable with proper staging upfront.”
Resectable vs unresectable pancreatic cancer at a glance
Factor | Resectable | Unresectable |
Vessel involvement | No major contact | Encases major artery |
Treatment intent | Curative surgery | Disease control only |
First-line approach | Surgery upfront | Chemotherapy first |
Five-year survival | Twenty to thirty percent | Under five percent |
Cases at diagnosis | Fifteen to twenty percent | Majority of patients |
What separates resectable from unresectable disease ?
It’s all about anatomy. Specifically, where the tumour sits in relation to the big vessels around the pancreas.
- Resectable. Tumour is in the pancreas, isn’t touching the superior mesenteric artery, celiac axis, or hepatic artery, and any contact with the portal or superior mesenteric vein is small enough to be reconstructed. Surgery here is being done with cure in mind.
- Borderline resectable. There’s some vessel contact, but not enough to rule surgery out. These cases almost always start with chemotherapy first, usually FOLFIRINOX or a gemcitabine combination, and the goal is to pull the tumour back from the vessel before anyone takes a scalpel to it.
- Locally advanced disease is a different conversation entirely. The artery is encased, the vessel can’t be reconstructed, and any surgeon attempting resection would do more harm than the cancer itself. Treatment becomes systemic chemotherapy with or without radiation.
- Metastatic. Once the cancer has reached the liver, the peritoneum, the lungs, or distant lymph nodes, surgery is off the table regardless of what the primary looks like. Chemotherapy now is about controlling progression and managing symptoms, not removing anything.
The classification isn’t a footnote in the report, it’s the single decision that drives everything that follows. Pancreatic cancer treatment routes from this point on, whether neoadjuvant chemotherapy, surgery, or palliation, all rest on getting this initial reading right, which often means a second pair of trained eyes on the imaging and EUS for tissue confirmation.
What changes between the two pathways ?
Once the category is set, the treatment route diverges sharply. Patients should know what each path actually looks like before agreeing to it.
- Surgery upfront for resectable cases. A Whipple procedure for head-of-pancreas tumours, distal pancreatectomy for body and tail. Both are major operations and recovery is at least three to four weeks. Five-year survival sits between twenty and thirty percent with surgery alone, better when adjuvant chemotherapy is added.
- For borderline cases, chemotherapy comes first. Three to six months of FOLFIRINOX or a similar regimen, then a restaging scan to see what’s happened. If the tumour has pulled back, surgery becomes possible. If not, the chemo response itself tells you something about the biology.
- Definitive chemoradiation for locally advanced disease. No operation, but aggressive systemic and local treatment can shrink the cancer, ease symptoms, and occasionally bring a patient back into resectable territory. Most of the time the goal is durable disease control.
- Palliative care for metastatic disease. Chemotherapy to slow progression, biliary stenting if jaundice develops, EUS-guided celiac plexus block for pain, and frank conversations about prognosis from the first consultation onwards.
Where a patient ends up depends entirely on how accurately the initial staging is done, which is why second opinions before any locked-in decision are common and reasonable. Read more on pancreatic cancer detection to understand why most of these cases are already past resectable by the time they’re picked up.
Why choose Dr. Vipulroy Rathod for pancreatic cancer assessment?
Dr. Vipulroy Rathod has been involved in staging and endoscopic assessment of pancreatic cancer at Fortis Hospital Mulund for over thirty years, with a particular focus on EUS-guided biopsy and the careful imaging review that decides resectability. Many of the patients we see arrive with a CT report calling their cancer operable, when a closer look at the vessel involvement tells a quite different story. Re-reading the scan properly often saves a patient from a surgery that was never going to succeed.
The first few decisions in pancreatic cancer are the most consequential. Get the staging right and the rest of the plan follows logically. Get it wrong and the patient loses months on the wrong pathway, which in this disease is time nobody has.
Book your consultation today with one of India’s most experienced specialists for pancreatic cancer staging and treatment planning.
Frequently Asked Questions
A contrast-enhanced CT looks at how the tumour sits in relation to the superior mesenteric artery, celiac axis, hepatic artery, and portal vein. There are specific criteria around degree of vessel contact that define each category, and the imaging is usually reviewed by both a radiologist and a surgical team before the final call is made.
Yes, and this happens often enough to be worth attempting. Neoadjuvant chemotherapy, sometimes paired with radiation, can shrink the tumour back from the involved vessel, and a restaging scan a few months later tells you whether resection is now safe.
Treatable yes, curable usually not. Chemotherapy and radiation can control the disease for a meaningful period, manage symptoms, and extend survival. A small group of patients respond well enough to be reconsidered for surgery down the line.
Five-year survival after surgery alone is roughly fifteen to twenty percent. It climbs to twenty-five to thirty percent or more when adjuvant chemotherapy is given. Smaller tumours, clear lymph nodes, and negative margins all push the number higher.
Reference links-
- Pancreatic Adenocarcinoma Guidelines, National Comprehensive Cancer Network — https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455
- Resectability Criteria and Staging, American Hepato-Pancreato-Biliary Association — https://www.ahpba.org/wp-content/uploads/2017/04/Consensus-Statement-on-Pancreatic-Cancer.pdf
